Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Theratechnologies Inc (TSX: TH )

1.810 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Theratechnologies Inc

< Previous 1 2 3 Next >
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
From Theratechnologies
Via GlobeNewswire
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
From Theratechnologies
Via GlobeNewswire
Theratechnologies Appoints Elina Tea to its Board of Directors
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Update on its Preclinical Oncology Research Program
From Theratechnologies
Via GlobeNewswire
Theratechnologies Appoints Jordan Zwick to its Board of Directors
From Theratechnologies
Via GlobeNewswire
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
From Theratechnologies
Via GlobeNewswire
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
From Theratechnologies
Via GlobeNewswire
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
From Theratechnologies
Via GlobeNewswire
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application
From Theratechnologies
Via GlobeNewswire
Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
From Theratechnologies
Via GlobeNewswire
Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award
Honor awarded last night recognizes Theratechnologies and Prof. Borhane Annabi for advancing preclinical development of sudocetaxel zendusortide for treatment of triple-negative breast cancer 
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Operational Update
From Theratechnologies
Via GlobeNewswire
Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon
From Theratechnologies
Via GlobeNewswire
Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration Study
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
From Theratechnologies
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.